Table 1.
Baseline description of the prevalent populations, year 2015, for Norway, Sweden, Denmark and Finland
| Denmark | Finland | Norway | Sweden | |
|---|---|---|---|---|
| No. of second‐line patients | 6343 | 9123 | 5019 | 13 395 |
| % of T2D full population | 3.5% | 2.5% | 2.8% | 3.8% |
| Time on metformin, mean years (SD) | 4.4 (2.9) | 5.0 (3.1) | 4.7 (3.2) | 4.8 (2.9) |
| Age, mean (SD) | 62.0 (12.7) | 65.3 (12.3) | 61.7 (12.8) | 65.0 (12.1) |
| Female, n | 2518 (39.7) | 4083 (44.8) | 1952 (38.9) | 5318 (39.7) |
| Comorbidities | ||||
| CVD | 1661 (26.2) | 3234 (35.5) | 1347 (26.8) | 4189 (31.3) |
| Myocardial infarction | 333 (5.2) | 667 (7.3) | 318 (6.3) | 1294 (9.7) |
| Unstable angina | 148 (2.3) | 487 (5.3) | 135 (2.7) | 605 (4.5) |
| Angina pectoris | 561 (8.8) | 923 (10.1) | 441 (8.8) | 1028 (7.7) |
| Heart failure | 360 (5.7) | 827 (9.1) | 306 (6.1) | 1000 (7.5) |
| Atrial fibrillation | 583 (9.2) | 1328 (14.6) | 445 (8.9) | 1424 (10.6) |
| Stroke | 332 (5.2) | 968 (10.6) | 240 (4.8) | 1254 (9.4) |
| Peripheral artery disease | 330 (5.2) | 499 (5.5) | 317 (6.3) | 643 (4.8) |
| Microvascular disease | 944 (14.9) | 1625 (17.8) | 950 (18.9) | 2202 (16.4) |
| Chronic kidney disease | 121 (1.9) | 105 (1.2) | 160 (3.2) | 170 (1.3) |
| Lower limb amputations | 25 (0.4) | 29 (0.3) | 13 (0.3) | 35 (0.3) |
| Cancera | 649 (10.2) | 1214 (13.3) | 502 (10.0) | 1271 (9.5) |
| Drug treatments | ||||
| CVD risk treatment | 5734 (90.4) | 8185 (89.7) | 4037 (80.4) | 11 929 (89.1) |
| Antihypertensives ACEi or ARBs | 4703 (74.1) | 7434 (81.5) | 3412 (68.0) | 10392 (77.6) |
| Statins | 4615 (72.8) | 5421 (59.4) | 2865 (57.1) | 8758 (65.4) |
| Low‐dose aspirin | 1789 (28.2) | — | 1689 (33.7) | 3931 (29.3) |
| Beta blockers | 1762 (27.8) | 4549 (49.9) | 1693 (33.7) | 5639 (42.1) |
| Second‐line treatment | ||||
| Time on metformin, mean years (SD) | 4.4 (2.9) | 5.0 (3.1) | 4.7 (3.2) | 4.8 (2.9) |
| DPP‐4i | 3555 (56.0) | 8165 (89.5) | 2763 (55.1) | 4551 (34.0) |
| SGLT‐2i | 360 (5.7) | 193 (2.1) | 536 (10.7) | 579 (4.3) |
| GLP‐1RA | 510 (8.0) | 46 (0.5) | 247 (4.9) | 769 (5.7) |
| Sulphonylurea | 1317 (20.8) | 120 (1.3) | 1121 (22.3) | 4068 (30.4) |
| Insulin | 597 (9.4) | 510 (5.6) | 328 (6.5) | 2451 (18.3) |
| Other | 4 (0.1) | 89 (1.0) | 24 (0.5) | 977 (7.3) |
ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CVD, cardiovascular disease.
a
Cancer diagnose within 5 years prior to index.